Ionis Pharmaceuticals, Inc. Operating Expenses
Ionis Pharmaceuticals, Inc. (IONS) reported Operating Expenses of $181.33 million for the 3-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2019-03-01
- Ionis Pharmaceuticals, Inc. operating expenses for the quarter ending 2018-12-31 was $181.33M, a 4.22% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating expenses for the quarter ending 2018-09-30 was $163.97M, a 53.24% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating expenses for the quarter ending 2018-06-30 was $168.03M, a 58.78% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating expenses for the quarter ending 2018-03-31 was $147.72M, a 53.37% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating expenses for fiscal 2018 was $661.05M, a 36.83% increase from fiscal 2017.
- Ionis Pharmaceuticals, Inc. operating expenses for fiscal 2017 was $483.13M, a 22.95% increase from fiscal 2016.
- Ionis Pharmaceuticals, Inc. operating expenses for fiscal 2016 was $392.94M, a 9.31% increase from fiscal 2015.
- Ionis Pharmaceuticals, Inc. operating expenses for fiscal 2015 was $359.46M, a 37.26% increase from fiscal 2014.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2018-12-31 | $181.33M 10-K · filed 2019-03-01 | $345.30M derived: sum of 2 quarters · filed 2019-03-01 | $513.33M derived: sum of 3 quarters · filed 2019-03-01 | $661.05M 10-K · filed 2019-03-01 |
| 2018-09-30 | $163.97M 10-K · filed 2019-03-01 | $332.00M derived: sum of 2 quarters · filed 2019-03-01 | $479.72M 10-Q · filed 2018-11-06 | $653.71M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-06-30 | $168.03M 10-K · filed 2019-03-01 | $315.75M 10-Q · filed 2018-08-07 | $489.74M derived: sum of 3 quarters · filed 2019-03-01 | $596.74M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-03-31 | $147.72M 10-K · filed 2019-03-01 | $321.71M derived: sum of 2 quarters · filed 2019-03-01 | $428.71M derived: sum of 3 quarters · filed 2019-03-01 | $534.54M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-12-31 | $173.99M 10-K · filed 2019-03-01 | $280.99M derived: sum of 2 quarters · filed 2019-03-01 | $386.82M derived: sum of 3 quarters · filed 2019-03-01 | $483.13M 10-K · filed 2019-03-01 |
| 2017-09-30 | $107.00M 10-K · filed 2019-03-01 | $212.82M derived: sum of 2 quarters · filed 2019-03-01 | $309.14M 10-Q · filed 2018-11-06 | $428.33M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $105.82M 10-K · filed 2019-03-01 | $202.14M 10-Q · filed 2018-08-07 | $321.33M derived: sum of 3 quarters · filed 2019-03-01 | $416.15M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $96.31M 10-K · filed 2019-03-01 | $215.51M derived: sum of 2 quarters · filed 2019-03-01 | $310.33M derived: sum of 3 quarters · filed 2019-03-01 | $397.73M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $119.19M 10-K · filed 2018-02-28 | $214.01M derived: sum of 2 quarters · filed 2018-02-28 | $301.41M derived: sum of 3 quarters · filed 2018-02-28 | $392.94M 10-K · filed 2019-03-01 |
| 2016-09-30 | $94.82M 10-K · filed 2018-02-28 | $182.22M derived: sum of 2 quarters · filed 2018-02-28 | $273.74M 10-Q · filed 2017-11-07 | $388.25M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $87.40M 10-K · filed 2018-02-28 | $178.92M 10-Q · filed 2017-08-09 | $293.43M derived: sum of 3 quarters · filed 2018-02-28 | $390.69M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $91.53M 10-K · filed 2018-02-28 | $206.04M derived: sum of 2 quarters · filed 2018-02-28 | $303.30M derived: sum of 3 quarters · filed 2018-02-28 | $379.08M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $114.51M 10-K · filed 2017-03-01 | $211.77M derived: sum of 2 quarters · filed 2017-03-01 | $287.55M derived: sum of 3 quarters · filed 2017-03-01 | $359.46M 10-K · filed 2018-02-28 |
| 2015-09-30 | $97.26M 10-K · filed 2017-03-01 | $173.04M derived: sum of 2 quarters · filed 2017-03-01 | $244.95M 10-Q · filed 2016-11-09 | $319.74M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $75.78M 10-K · filed 2017-03-01 | $147.69M 10-Q · filed 2016-08-09 | $222.48M derived: sum of 3 quarters · filed 2017-03-01 | $288.03M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $71.91M 10-K · filed 2017-03-01 | $146.69M derived: sum of 2 quarters · filed 2017-03-01 | $212.25M derived: sum of 3 quarters · filed 2017-03-01 | $275.98M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $74.78M 10-K · filed 2016-02-26 | $140.34M derived: sum of 2 quarters · filed 2016-02-26 | $204.06M derived: sum of 3 quarters · filed 2016-02-26 | $261.89M 10-K · filed 2017-03-01 |
| 2014-09-30 | $65.56M 10-K · filed 2016-02-26 | $129.28M derived: sum of 2 quarters · filed 2016-02-26 | $187.11M 10-Q · filed 2015-11-09 | $249.22M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $63.73M 10-K · filed 2016-02-26 | $121.55M 10-Q · filed 2015-08-05 | $183.66M derived: sum of 3 quarters · filed 2016-02-26 | $232.75M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $57.83M 10-K · filed 2016-02-26 | $119.93M derived: sum of 2 quarters · filed 2016-02-26 | $169.02M derived: sum of 3 quarters · filed 2016-02-26 | $215.04M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $62.11M 10-K · filed 2015-03-02 | $111.20M derived: sum of 2 quarters · filed 2015-03-02 | $157.22M derived: sum of 3 quarters · filed 2015-03-02 | $198.95M 10-K · filed 2016-02-26 |
| 2013-09-30 | $49.09M 10-K · filed 2015-03-02 | $95.11M derived: sum of 2 quarters · filed 2015-03-02 | $136.84M 10-Q · filed 2014-11-07 | $182.84M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $46.02M 10-K · filed 2015-03-02 | $87.75M 10-Q · filed 2014-08-04 | $133.75M derived: sum of 3 quarters · filed 2015-03-02 | $173.39M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $41.73M 10-K · filed 2015-03-02 | $87.73M derived: sum of 2 quarters · filed 2015-03-02 | $127.37M derived: sum of 3 quarters · filed 2015-03-02 | $171.02M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $45.99M 10-K · filed 2014-03-03 | $85.64M derived: sum of 2 quarters · filed 2014-03-03 | $129.28M derived: sum of 3 quarters · filed 2014-03-03 | $170.97M 10-K · filed 2015-03-02 |
| 2012-09-30 | $39.65M 10-K · filed 2014-03-03 | $83.29M derived: sum of 2 quarters · filed 2014-03-03 | $124.98M 10-Q · filed 2013-11-05 | $176.00M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $43.64M 10-K · filed 2014-03-03 | $85.33M 10-Q · filed 2013-08-06 | $136.35M derived: sum of 3 quarters · filed 2014-03-03 | $179.38M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $41.69M 10-K · filed 2014-03-03 | $92.71M derived: sum of 2 quarters · filed 2014-03-03 | $135.74M derived: sum of 3 quarters · filed 2014-03-03 | $174.62M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | $51.02M 10-K · filed 2013-02-28 | $94.05M derived: sum of 2 quarters · filed 2013-02-28 | $132.93M derived: sum of 3 quarters · filed 2013-02-28 | $170.19M 10-K · filed 2014-03-03 |
| 2011-09-30 | $43.03M 10-K · filed 2013-02-28 | $81.91M derived: sum of 2 quarters · filed 2013-02-28 | $119.17M 10-Q · filed 2012-11-06 | $161.44M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | $38.88M 10-K · filed 2013-02-28 | $76.14M 10-Q · filed 2012-08-06 | $118.42M derived: sum of 3 quarters · filed 2013-02-28 | $155.99M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $37.26M 10-K · filed 2013-02-28 | $79.53M derived: sum of 2 quarters · filed 2013-02-28 | $117.10M derived: sum of 3 quarters · filed 2013-02-28 | $159.28M derived: sum of 4 quarters · filed 2013-02-28 |
| 2010-12-31 | $42.28M 10-K · filed 2012-02-29 | $79.85M derived: sum of 2 quarters · filed 2012-02-29 | $122.02M derived: sum of 3 quarters · filed 2012-02-29 | $156.83M 10-K · filed 2013-02-28 |
| 2010-09-30 | $37.57M 10-K · filed 2012-02-29 | $79.75M derived: sum of 2 quarters · filed 2012-02-29 | $114.55M 10-Q · filed 2011-11-08 | $158.49M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $42.17M 10-K · filed 2012-02-29 | $76.98M 10-Q · filed 2011-08-08 | $120.92M derived: sum of 3 quarters · filed 2012-02-29 | $158.08M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $34.81M 10-K · filed 2012-02-29 | $78.74M derived: sum of 2 quarters · filed 2012-02-29 | $115.91M derived: sum of 3 quarters · filed 2012-02-29 | $151.73M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $43.93M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $81.10M derived: sum of 2 quarters · filed 2012-02-29 | $116.92M derived: sum of 3 quarters · filed 2012-02-29 | $149.14M 10-K · filed 2012-02-29 |
| 2009-09-30 | $37.17M 10-Q · filed 2010-11-05 | $72.99M derived: sum of 2 quarters · filed 2010-11-05 | $105.20M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $35.82M 10-Q · filed 2010-08-09 | $68.04M 10-Q · filed 2010-08-09 | ||
| 2008-12-31 | $120.25M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |